Byterna Therapeutics Secures Angel+ Financing to Advance First-in-Class Circular mRNA In Vivo CAR-T Therapy into IIT Clinical Trials

Recently, focusing on the loopZhuang RNAByterna Therapeutics: A New Drug Development Company for In-body CAR-T Therapy（Byterna Therapeutics）Announced the completion of the Angel+ round of financing, with this round of investment fromYifeng Zhuohua Fund.Funds raised will be mainly used to advance the development of circular mRNA in vivo CAR-T therapy.IITClinical trial.

This financing is the second round of funding completed by Byterna Therapeutics within two months. Previously, the company had received funding led by Sunshine Nova on October 17 this year.Fangfu Venture Capital and others followed the investment.Tens of millions of yuan in angel round financing.

Founded in June 2023Byterna Therapeutics is a cutting-edge technology company headquartered in Zhangjiang, Shanghai. Relying on leading circular RNA and in vivo CAR-T technology platforms, it is committed to developing innovative drugs that are "safe, effective, accessible, and affordable," promoting the clinical application of CAR-T therapy in major disease areas such as autoimmune diseases and malignant tumors, and addressing unmet medical needs.

Circular RNA, as an RNA molecule with a covalently closed loop and stable structure, has been hailed by Nature magazine as "the next big thing in RNA therapeutics." It shows great promise in areas such as vaccines, protein replacement, and cell and gene therapy (CGT). However, its industrialization faces technical bottlenecks in sequence design and chemical modification, especially as chemical modifications are difficult to make compatible with the circular structure, hindering drug development. Byterna Therapeutics, with its deep original expertise in AI-driven circular RNA sequence design and site-specific modification technology, is accelerating the construction of an intelligent technology platform, which is expected to be the first to overcome the globally common challenge of chemical modification.

By deeply integrating circular RNA technology with in vivo CAR-T therapy, Byterna Therapeutics is committed to building a "Best-in-Class" mRNA CAR-T in vivo therapy technology platform, accelerating the clinical translation of innovative therapies. Currently,Byterna TherapeuticsIs accelerating the advancement of the circularRNA-based CAR-T Therapy In VivoThe research is expected to be the first to advance modified circular mRNA-based CAR-T therapy in vivo into clinical trials, becoming the world's first such therapy to enter clinical research.

Notably, in recent years, several large pharmaceutical companies have shown strong interest in "in vivo CAR-T cell therapy," with multiple high-profile acquisitions completed this year: AstraZeneca acquired EsoBiotech for $1 billion in March; AbbVie purchased Capstan Therapeutics for $2.1 billion in June; and Kite Pharma, a subsidiary of Gilead Sciences, spent $350 million to acquire Interius BioTherapeutics in August. As relevant policies shift and technology continues to advance, in vivo cell therapies, including in vivo CAR-T, are becoming the new frontier in the next generation of precision medicine competition.

E.N.D

ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following information when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also specify.